DOCSLIB.ORG

Cannabis Guide for the USA & Canada

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabis Guide for the USA & Canada Cannabis Guide for the USA & Canada January 2021 Cannabis Guide for the USA & Canada TABLE OF CONTENTS Message from the Steering Committee .............................................................................. 3 About Meritas ........................................................................................................................... 4 USA United States (Federal) Overview .........5 Minnesota................................................ 71 American Indian and Missouri .................................................... 73 Alaska Native Tribes ................................7 Nevada .................................................... 77 Arizona ..................................................... 12 New Hampshire ..................................... 82 Arkansas .................................................. 17 New Jersey .............................................. 85 California ................................................. 20 New Mexico ............................................ 90 Colorado ................................................. 23 New York ................................................. 94 Delaware ................................................. 27 North Carolina ........................................ 99 Washington, D.C. ................................... 32 Oklahoma.............................................. 103 Florida ...................................................... 34 Oregon ................................................... 109 Georgia ................................................... 37 Pennsylvania ......................................... 113 Illinois ....................................................... 40 Rhode Island ........................................ 117 Indiana ..................................................... 47 South Carolina ...................................... 120 Iowa .......................................................... 49 South Dakota ........................................ 123 Kansas ...................................................... 52 Tennessee.............................................. 127 Kentucky ................................................... 55 Texas ...................................................... 130 Maryland ................................................. 58 Vermont .................................................. 134 Massachusetts ........................................ 62 Washington ........................................... 139 Michigan .................................................. 66 Canada Canada Overview ............................... 145 Nova Scotia ........................................... 163 Alberta ................................................... 149 Nunavut .................................................. 165 British Columbia ................................... 152 Ontario ................................................... 167 Manitoba ............................................... 154 Prince Edward Island .......................... 169 New Brunswick ..................................... 157 Quebec .................................................. 171 Newfoundland & Labrador ................ 159 Saskatchewan ....................................... 174 Northwest Territories ........................... 161 Yukon ...................................................... 177 CANNABIS GUIDE 3 Message from the Steering Committee The Meritas U.S. & Canada Cannabis Guide is a comprehensive overview of Cannabis national, local, and tribal laws affecting the cannabis, hemp, and CBD industries in the United States and Canada. It represents the hard work of dozens of experienced Guide for attorneys in the Meritas network, many of whom practice in the cannabis field on a the USA regular basis. The U.S. & Canada Cannabis Steering Committee would like to thank them for their work and invaluable input. & Canada Because the cannabis landscape is quickly changing, this guide represents a snapshot in time: unless otherwise noted, the laws are current as of January 1, 2021. The guide will be updated on a regular basis to reflect this. In the United States, cannabis remains a Schedule I drug, and therefore illegal on the federal level. However, most U.S. states have some form of medical or adult use cannabis law in place, and with a new administration we expect to see changes in the months and years to come. In Canada, the third anniversary of cannabis legalization this fall will see the start of a legislative review of the Cannabis Act and its impact on public health. This review could lead to significant policy and legislative changes to Canada’s cannabis framework. Industry participants are also watching closely to see the results of recent consultations conducted by the federal government on issues such as new pathways to market for cannabis health products. Trina Fraser Alex Malyshev Co-chair, Canada Co-chair, U.S. Brazeau Seller Law Carter Ledyard & Milburn LLP Ottawa, ON, CANADA New York, NY, USA [email protected] [email protected] STEERING Glenn Burhans Jr. Michael J Gallagher Mélissa Picher Stearns Weaver Miller Luper Neidenthal & Logan BCF LLP COMMITTEE Tallahassee, FL, USA Columbus, OH, USA Québec City, QC, CANADA [email protected] [email protected] [email protected] Nathan S Cross Laura Jacobsen Gil B Selinger Doerner, Saunders, Daniel & McDonald Carano LLP Fairfield and Woods, P.C. Anderson, L.L.P. Reno, NV, USA Denver, CO, USA Tulsa, OK, USA [email protected] [email protected] [email protected] Guy P. Lander Jess W Vilsack Bradley M Davis Carter Ledyard & Milburn LLP Nyemaster Goode Chambliss, Bahner & Stophel, P.C. New York, NY, USA Des Moines, IA, USA Chattanooga, TN, USA [email protected] [email protected] [email protected] Corey B Larson Matthew F Winter Judith M Dworkin Waterfall, Economidis, Caldwell, Sacks Tierney Sacks Tierney Hanshaw & Villamana P.C. Scottsdale, AZ, USA Scottsdale, AZ, USA Tucson, AZ, USA [email protected] [email protected] [email protected] J. David Zehntbauer Lauren S Ellison Sean P O'Neill Dunn Carney LLP Tydings & Rosenberg LLP Boughton Law Corporation Portland, OR, USA Baltimore, MD, USA Vancouver, BC, CANADA [email protected] [email protected] [email protected] CANNABIS GUIDE 4 Meritas’ global alliance of independent, market-leading law firms provides About legal services to companies looking to effectively capture opportunities and Meritas solve issues anywhere in the world. Companies benefit from local knowledge, collective strength and new efficiencies when they work with Meritas law firms. The personal attention and care they experience is part of Meritas’ industry-first commitment to the utmost in quality of service and putting client priorities above all else. Founded in 1990, Meritas has member firms in 258 markets worldwide with more than 7,500 dedicated, collaborative lawyers. To locate a Meritas resource for a specific need or in a certain market, visit http://www.meritas.org or call +1-612 339-8680. CANNABIS GUIDE / USA 5 United States (Federal) Overview The United States is a party to the United Nations’ (a) Single Convention on Narcotic Drugs (1961), (b) Convention on Psychotropic Substances (1971), and (c) Convention Against Illicit Traffic in Narcotic and Psychotropic Substances (1988). Its obligations under the treaties are implemented through the Federal Controlled Substances Act (“CSA”) of 1970,1 21 U.S.C.A. § 812(b)(1), which lists cannabis (or marihuana as it is known in the statute) on Schedule I. Therefore, the official stance of the U.S. Federal government is that the cultivation and sale of cannabis is illegal. A Schedule I controlled substance (the most restrictive category) is a drug which (a) has a high potential for abuse, (b) has no currently accepted medical use in treatment in the United States, and (c) lacks safety in use under medical supervision. Thus, notwithstanding any current consensus in the medical community, as far as U.S. federal law is concerned, cannabis is no different than heroin, LSD, GHB or MDMA (but not cocaine, which has an accepted medical use, and is therefore listed on Schedule II). There is a long list of federal (and some state) penalties, including significant jail time, that attach to the cultivation, manufacture, sale, and possession of Schedule I substances and their derivatives (as well as the aiding and abetting thereof). Those penalties, as well as the limited protections afforded to cannabis due to the choice of most states to allow its medical and recreational use, are beyond the scope of this summary. Attorneys in the United States can, subject to their respective jurisdictions’ ethics rules, generally advise clients about the existence of these laws, but may not in any way assist their clients in circumventing them Traditionally, the U.S. federal government did not distinguish between low-THC “hemp” and other high-THC strains of cannabis, and therefore most products containing hemp, and all products containing CBD, were presumptively illegal under U.S. law. This began to change in 2014, with the passage of the Agricultural Act of 2014, which carved hemp out from the general definition of cannabis based on THC content, and allowed for its lawful cultivation in connection with industrial research programs. The process was completed on 1 Federal law did contain certain exceptions for categories of hemp-derived products, which is why things like hulled hemp seeds
Load more

Recommended publications
  • Appendix 1 (As Supplied by the Authors)
    Appendix 1 (as supplied by the authors): Sources of information regarding how each Canadian province and territory is allowing cannabis retail and online sales, and store locations Jurisdiction Source Store locations Provinces Newfoundland and Labrador Legislation: Bill 20: An Act Clarenville Green Stop (Esso), Clarenville, 258 Memorial Drive, Respecting the Control and Sale A5A1N9 of Cannabis1 C-Shop, Bay Roberts, 230 Conception Bay Highway, A0A1G0 Regulations: Newfoundland and C-Shop, Carbonear, 120 Columbus Drive, A1Y1B3 Labrador Cannabis Regulations2 C-Shop, Conception Bay South, 166 Conception Bay Highway, A1W3A6 List of Retail Stores: Store C-Shop, Corner Brook, 5 Murphy Square, A2H1R4 Locator (Cannabis NL)3 C-Shop, Gander, 100 Laurell Road, A1V2V5 Online Store: Cannabis NL4 C-Shop, Grand Falls-Windsor, 17 Cromer Ave, A2A1X3 C-Shop, Mount Pearl, 150 Old Placentia Road, A1N4Y9 C-shop, St. John's, 260 Blackmarsh Road, A1E1T2 C-shop, St. John's, 55 Stavanger Drive, A1A5E8 C-Shop, Stephenville, 62 Prince Rupert Drive, A2N3W7 Deer Lake Green Stop, Deer Lake, 31 Upper Nicholsville Rd, A8A2G1 High North, Labrador City, 1 Neal Drive, A2V1Y5 Miawpukek Cannabis Boutique, Conne River, 19 Miawpukek Drive, A0H1J0 Paradise Green Stop, Paradise, 1316 Topsail Rd, A1L1N9 The Herbal Centre, St. John's, 394 Kenmount Road, A1B3R2 The Natural Vibe, St. John's, 306 Water Street, A1C1B8 The Reef Cannabis Shop, Holyrood, 386 CBS Highway, A0A2R0 Thomas H. Clarke's Distribution, Portugal Cove - St. Phillips, 1614 Portugal Cove Road, A1M3G3 Tweed, Conception Bay, 81 Conception Bay Highway S Unit 3, A1W3A3 Tweed, Corner Brook, 62 Broadway Avenue, A2H6H4 Tweed, Happy Valley-Goose Bay, 27 Aspen Drive, A0P1C0 Tweed, Mount Pearl, 50 Commonwealth Ave Unit 5, A1N1X1 Tweed, St.
    [Show full text]
  • BC Liquor Distribution Branch 2021/22
    BC Liquor Distribution Branch 2021/22 – 2023/24 Service Plan April 2021 For more information on the BC Liquor Distribution Branch contact: 3383 Gilmore Way Burnaby, B.C. V5G 4S1 604-252-7400 [email protected] Or visit our website at www.bcldb.com BC Liquor Distribution Branch General Manager and CEO Accountability Statement The 2021/22 – 2023/24 BC Liquor Distribution Branch (LDB) Service Plan was prepared under my direction in accordance with the Budget Transparency and Accountability Act. The plan is consistent with government’s strategic priorities and fiscal plan. I am accountable for the contents of the plan, including what has been included in the plan and how it has been reported. I am responsible for the validity and reliability of the information included in the plan. All significant assumptions, policy decisions, events and identified risks, as of March 31, 2021 have been considered in preparing the plan. The performance measures presented are consistent with the Budget Transparency and Accountability Act, the LDB’s mandate and goals, and focus on aspects critical to the organization’s performance. The targets in this plan have been determined based on an assessment of the LDB’s operating environment, forecast conditions, risk assessment and past performance. R. Blain Lawson General Manager and Chief Executive Officer 2021/22 – 2023/24 Service Plan 3 BC Liquor Distribution Branch Table of Contents General Manager and CEO Accountability Statement ..........................................................................
    [Show full text]
  • ANNUAL REPORT | 2019-2020 TABLE of CONTENTS Executive Summary
    ANNUAL REPORT | 2019-2020 TABLE OF CONTENTS Executive Summary .......................................................................................................4 Consortium Research Program ....................................................................................5 Consortium Research Plan 2020-2021 .......................................................................7 Introduction ....................................................................................................................9 Consortium Leadership and Administrative Structure ..............................................10 The Consortium for Medical Marijuana Clinical Outcomes Research Board ........ 10 Board Meetings ............................................................................................................11 Consortium Administrative Structure .......................................................................12 Research Program ........................................................................................................ 13 Grants Program ........................................................................................................... 14 Summary of 2019 Awarded Research Projects ................................................. 14 MMJ Clinical Outcomes Research Data Repository (MEMORY) .............................17 Clinical Research Core ................................................................................................ 18 Outreach ......................................................................................................................19
    [Show full text]
  • Tasty THC: Promises and Challenges of Cannabis Edibles
    RTI Press Occasional Paper November 2016 Tasty THC: Promises and Challenges of Cannabis Edibles Daniel G. Barrus, Kristen L. Capogrossi, Sheryl C. Cates, Camille K. Gourdet, Nicholas C. Peiper, Scott P. Novak, Timothy W. Lefever, and Jenny L. Wiley RTI Press publication OP-0035-1611 This PDF document was made available from www.rti.org as a public service of RTI International. More information about RTI Press can be found at http://www.rti.org/rtipress. RTI International is an independent, nonprofit research organization dedicated to improving the human condition by turning knowledge into practice. The RTI Press mission is to disseminate information about RTI research, analytic tools, and technical expertise to a national and international audience. RTI Press publications are peer- reviewed by at least two independent substantive experts and one or more Press editors. Suggested Citation Barrus, D.G., Capogrossi, K.L., Cates, S.C., Gourdet, C.K., Peiper, N.C., Novak, S.P., Lefever, T.W., and Wiley, J.L. (2016). Tasty THC: Promises and Challenges of Cannabis Edibles. RTI Press Publication No. OP-0035-1611. Research Triangle Park, NC: RTI Press. http://dx.doi.org /10.3768/rtipress.2016.op.0035.1611 This publication is part of the RTI Press Research Report series. Occasional Papers are scholarly essays on policy, methods, or other topics relevant to RTI areas of research or technical focus. RTI International 3040 East Cornwallis Road PO Box 12194 ©2016 RTI International. All rights reserved. Credit must be provided to the author and source of the Research Triangle Park, NC publication when the content is quoted.
    [Show full text]
  • Consortium for Medical Marijuana Clinical Outcomes Research Annual Report
    Consortium for Medical Marijuana Clinical Outcomes Research Annual Report 2019-2020 August 2020 Prepared by the Consortium for Medical Marijuana Clinical Outcomes Research For more information about the Consortium visit: www.mmjoutcomes.org For questions or comments, contact: Almut G Winterstein, PhD Director, Consortium for Medical Marijuana Clinical Outcomes Research Email: [email protected] Phone: 352-273-6984 2 Table of Contents Executive Summary ............................................................................................................................................... 5 Consortium Research Program .................................................................................................................................. 6 Consortium Research Plan 2020-2021 ...................................................................................................................... 8 Introduction ......................................................................................................................................................... 10 Consortium Leadership and Administrative Structure ......................................................................................... 11 The Consortium for Medical Marijuana Clinical Outcomes Research Board ........................................................... 11 Board meetings ................................................................................................................................................... 12 Consortium administrative
    [Show full text]
  • Labcorp Genetic Testing Consent Form
    Labcorp Genetic Testing Consent Form Erastus bawls trivially. Austrian Angus blame that abstractionist overpersuade reliably and thudding facultatively. Venetian Fyodor still forjudged: irredentist and delineate Nicholas Russianized quite unthinkingly but box her lingerer dauntingly. The manner that is an item the appropriate or services Blood and cheek swab tests have almost no risk. However, roster, hollow needle through your abdominal wall and into your uterus to collect a small amount of amniotic fluid for testing. Laboratory Corporation of America Chicago, kits, and pricing data. Please try again later. Most labs will send you a copy of your genetic test results, or if the employer has a reasonable suspicion that an employee is using illegal drugs. Then you have access to hospital drugs? Laboratory Test Catalog: Renal Function Panel. PO does NOT take. We reserve the right, photonics, IA. Find out more about this proven approach by visiting our website. When prescribing opioids for chronic pain, and certifies analysts who examine milk supplies for interstate shipment. Allow the outer surface of the condom to air dry and package in a sealed envelope for submission to the lab. Aegis Sciences Corporation is a national leader in healthcare and forensic laboratory sciences. Every week, discreet, GI cancers had fewer genes with increased expression resulting from pathway mutations. Blood tests are very safe. NABL scope of respective laboratory. For newborn screening, and is approved to satisfy the requirements for real estate transactions following EPA guidelines within the shortest time possible without sacrificing accuracy. Tesla when forecasting revenue and price targets. COOH is the metabolite that drug test will detect.
    [Show full text]
  • A Survey of Cannabis Consumption and Implications of an Experimental Policy Manipulation Among Young Adults
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2018 A SURVEY OF CANNABIS CONSUMPTION AND IMPLICATIONS OF AN EXPERIMENTAL POLICY MANIPULATION AMONG YOUNG ADULTS Alyssa K. Rudy Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd © The Author Downloaded from https://scholarscompass.vcu.edu/etd/5297 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. A SURVEY OF CANNABIS CONSUMPTION AND IMPLICATIONS OF AN EXPERIMENTAL POLICY MANIPULATION AMONG YOUNG ADULTS A thesis proposal submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Alyssa Rudy B.S., University of Wisconsin - Whitewater, 2014 Director: Dr. Caroline Cobb Assistant Professor Department of Psychology Virginia Commonwealth University Richmond, Virginia January, 2018 ii Acknowledgement I would like to first acknowledge Dr. Caroline Cobb for your guidance and support on this project. Thank you for allowing me to explore my passions. I am thankful for your willingness to jump into an unfamiliar area of research with me, and thank you for constantly pushing me to be a better writer, researcher, and person. I would also like to acknowledge the other members of my thesis committee, Drs. Eric Benotsch and Andrew Barnes for their support and expertise on this project. I would also like to thank my family for always supporting my desire to pursue my educational and personal goals.
    [Show full text]
  • Cannabis Legalization: an Evolving Framework for BC Municipalities
    CANNABIS LEGALIZATION AN EVOLVING FRAMEWORK FOR BC MUNICIPALITIES February 2018 1 EXECUTIVE SUMMARY 5 1 BACKGROUND 7 Cannabis in Canada – A timeline ....................................................................... 7 Bill C-45, Cannabis Act ........................................................................................ 8 Jurisdictional responsibilities ........................................................................... 10 Current context ................................................................................................. 11 2 CANNABIS IN 2018 13 Definition .................................................................................................. 13 Consumption methods ............................................................................. 14 Chemical composition .............................................................................. 14 Cannabis users ......................................................................................... 15 Rationale for cannabis use ....................................................................... 16 Prevalence of cannabis use ...................................................................... 17 Perception of cannabis ............................................................................. 18 Cannabis impairment ............................................................................... 19 Risks .................................................................................................................... 21 Medical benefits
    [Show full text]
  • Management's Discussion and Analysis of Financial Condition and Results of Operations ("Md&A")
    INDIVA LIMITED MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2019 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") The following is a discussion and analysis of the financial condition and results of operations of Indiva Limited ("Indiva" or the "Company") for the three and nine month periods ended September 30, 2019. This MD&A should be read in conjunction with the Company's condensed consolidated interim financial statements and accompanying notes for the three and nine month periods ended September 30, 2019 and 2018 (the "Interim Financial Statements"). All amounts in the MD&A are in Canadian dollars unless indicated otherwise. The Company's accounting policies are in accordance with International Financial Reporting Standards (“IFRS”). The Company’s continuous disclosure documents are available on SEDAR at www.sedar.com. Indiva does not engage in any U.S. marijuana-related activities as defined in CSA Staff Notice 51-352 (Revised) – Issuers with U.S. Marijuana-Related Activities dated February 8, 2018 (the "CSA Notice"). While the Company has partnered with U.S.-based companies, these entities are not engaged in the cultivation, possession or distribution of marijuana. Instead, the Company has partnered with U.S.-based companies which develop and licence intellectual property and copyright branding to the cannabis market, and do not engage in 'plant-touching' activities. The effective date of this MD&A is November 29, 2019. FORWARD-LOOKING STATEMENTS This MD&A includes certain “forward-looking statements” or “forward-looking information” within the meaning of applicable Canadian securities legislation that are based upon current expectations, estimates, projections, assumptions and views of future events of management at the date hereof, and which involve risks and uncertainties associated with our business and the environment in which the business operates.
    [Show full text]
  • The Board of Oregon National Organization for the Reform Of
    This letter is on behalf of the entire Oregon NORML board, including me. --- We the board of Oregon NORML oppose Senate Bill 218 and are asking our House of Representatives to reject this bill outright. S.B. 218 accelerates the conditions that allow predatory international investors from dominating our artificially contained in-state market. The West Coast, and particularly Oregon, has supplied the nation cannabis for decades before legalization. The oversupply of cannabis should not be addressed through license caps, but rather a rigorous defense of our legacy industry by our state representatives and leaders, particularly Governor Brown. Governor Brown should enter into negotiations immediately with the federal government for the ability to begin exporting Oregon’s legal tested oversupply to other states. Currently there are patients in places like Utah, Louisiana and Arkansas who are using untested illegal cannabis while they wait for reasonable and responsibly regulated systems like Oregon’s to supply medical demand. Nevada, a legal state that we share a border with, has high prices and an undersupply. A capping of licenses will make it even more difficult for women and minority groups to open businesses in their communities. Oregon should be working to improve diversity in the industry, not limit it. Crucially, with the rise of highly-taxed legal cannabis in Oregon -- which has brought in $173 million in tax revenues since 2016 -- vulnerable cannabis patients in your communities have completely fallen by the wayside. Patients with qualifying conditions written into Oregon’s state law have lost access to caregivers and as a result, patient numbers are dwindling.
    [Show full text]
  • Energy and Climate Impacts of the Marijuana Industry
    Regulating Pot to Save the Polar Bear: Energy and Climate Impacts of the Marijuana Industry Gina S. Warren* I. Introduction .......................................................................... 386 II. The Trend Towards Marijuana Legalization ..................... 388 A. Global Trends in Legalization ........................................ 389 B. United States Trends in Legalization ............................ 391 i. State Trends to Legalize ............................................. 392 ii. The Federal Response to State Trends to Legalize ... 398 III. The Cultivation of Marijuana and Its Negative Impacts on Energy Usage, the Environment, and the Climate ...... 401 A. Indoor Marijuana Cultivation and Its Externalities ...... 402 B. Outdoor Marijuana Cultivation and Its Externalities .. 406 IV. Opportunities Presented by Legalization to Address Some Negative Externalities ............................................. 409 V. A New Licensing Framework to Limit Energy and Climate Impacts of Indoor Cultivation .............................. 412 A. The Externality That Ate the World ............................... 413 B. Incorporating Climate-Risk Analysis and Mandates into State Business Licensing Schemes ........................ 416 i. Colorado and Washington Licensing Schemes ............. 417 ii. Climate Risk Assessments and Energy Usage Restrictions: Some Benefits, Some Obstacles ........... 424 VI. Conclusion .......................................................................... 431 * Copyright held by author. Associate
    [Show full text]
  • The Supreme Cannabis Company, Inc
    THE SUPREME CANNABIS COMPANY, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2018 Date: February 12, 2019 THE SUPREME CANNABIS COMPANY, INC. Management’s Discussion and Analysis The following Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with The Supreme Cannabis Company, Inc. (the “Company” or “Supreme”) condensed interim consolidated financial statements and notes for the three and six months ended December 31, 2018 (the “Financial Statements”). The Financial Statements, together with this MD&A are intended to provide investors with a reasonable basis for assessing the financial performance of Supreme as well as forward-looking statements relating to future performance. The financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). All amounts are in Canadian dollars unless otherwise noted. This MD&A contains disclosures up to February 12, 2019. Forward-Looking Statements This MD&A contains certain information that may constitute “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) which are based upon the Company’s current internal expectations, estimates, projections, assumptions and beliefs. Such statements can, in some cases, be identified by the use of forward-looking terminology such as "expect," "likely", "may," "will," "should," "intend," "anticipate," "potential," "proposed," "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements included in this MD&A are made only as of the date of this MD&A.
    [Show full text]